Utilization and prescribing Pattern of rivaroxaban in a large teaching hospital in Iran

Document Type : Research Paper


1 Department of Clinical Pharmacy and Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran

2 School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran

3 Health Management and Economics Research Center, Isfahan University of Medical Sciences, Isfahan, Iran; AND Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy and Pharmaceutical Sciences, Isfahan University

4 Department of Internal Medicine, Alzahra Hospital, Isfahan University of Medical Sciences, Isfahan, Iran



This medication utilization evaluation aims to describe the use of rivaroxaban in a tertiary care teaching hospital and to audit the hospital physician’s prescribing practice. A prospective cross-sectional study was performed from March to December 2019 in Alzahra teaching hospital, Isfahan, Iran. All patients who received at least one dose of rivaroxaban were eligible for inclusion. Data were collected on patient demographics, indication, dosing regimen, adverse events, concurrent anticoagulant therapy and laboratory tests (including renal function). A total of 104 patients were included in our study. The majority of patients (N=39, 37.5%) was prescribed rivaroxaban for deep vein thrombosis (DVT) prophylaxis. Overall, more than 34% of rivaroxaban prescriptions was appropriate. Rivaroxaban was indicated correctly in all the patients (100% appropriate indication), however, 58.6% and 50% of patients received correct dosing, based on indication and renal function, respectively. High-dose prescribing was the major fault of prescriptions when the renal function was taken into account (82.6%). Appropriate switch occurred in 48.7% of the patients who switched from one anticoagulant to another. Inappropriate prescription of rivaroxaban for many patients in the current study, emphasizes the requirement of developing a scientifically well-defined protocol for the use of rivaroxaban in the evaluated hospital. Accordingly, establishment of a structured educational program for prescribers as well as assigning the rivaroxaban prescription to specialized services with consultation with clinical pharmacists is recommended.


[1] Di Minno A, et al. Old and new oral anticoagulants: food, herbal medicines and drug interactions. Blood. Rev. (2017) 31(4):193-203.
[2] Ruff CT, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet (2014)383(9921):955-62.
[3] Stacy Z. Novel oral anticoagulants for venous thromboembolism prophylaxis after total hip or knee replacement: an update on rivaroxaban (Xarelto). Pharm. Ther. (2013)38(1):45.
[4] Fox KA, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Europ. Heart. J. (2011)32(19):2387-94.
[5] Investigators EP. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New. Engl. J. Med. (2012)366(14):1287-97.
[6] Kreutz R. Pharmacokinetics and pharmacodynamics of rivaroxaban–an oral, direct factor Xa inhibitor. Curr. Clin. Pharm. (2014)9(1):75-83.
[7] Mueck W, Stampfuss J, Kubitza D, Becka M. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin. Pharmacokinetics. (2014)53(1):1-16.
[8] Kubitza D, et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Brit. J. Clin. Pharmacol. (2010)70(5):703-12.
[9] Mueck W, Kubitza D, Becka M. Co‐administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Brit. J. Clin. Pharmacol. (2013)76(3):455-66.
[10] Sherid M, et al. Risk of gastrointestinal bleeding with rivaroxaban: a comparative study with warfarin. Gastroenterol. Res. Pract. (2016) 2016: 9589036.
[11] Raschi E, et al. Liver injury with novel oral anticoagulants: assessing post‐marketing reports in the US Food and Drug Administration adverse event reporting system. Brit. J. Clin. Pharmacol. (2015)80(2):285-93.
[12] Kaatz S, Bhansali H, Gibbs J, Lavender R, Mahan CE, Paje DG. Reversing factor Xa inhibitors–clinical utility of andexanet alfa. J. Blood. Med .(2017) 8:141.
[13] Trujillo T, Dobesh PP. Clinical use of rivaroxaban: pharmacokinetic and pharmacodynamic rationale for dosing regimens in different indications. Drugs (2014)74(14):1587-603.
[14] Mayet AY, Alsaqer AI, Alhammad AM, Al-Omar HA. Rivaroxaban prescribing in a Saudi tertiary care teaching hospital. Saudi Pharmaceutical Journal (2018)26(6):775-9.
[15] Whitworth MM, Haase KK, Fike DS, Bharadwaj RM, Young RB, MacLaughlin EJ. Utilization and prescribing patterns of direct oral anticoagulants. Int. J. Gen. Med. (2017)10:87.
[16] Tellor K, Patel S, Armbruster A, Daly M. Evaluation of the appropriateness of dosing, indication and safety of rivaroxaban in a community hospital. J. Clin. Pharm. Ther. (2015) 40(4):447-51.
[17] Isaacs AN, Doolin M, Morse C, Shiltz E, Nisly SA. Medication utilization evaluation of dabigatran and rivaroxaban within a large, multi-center health system. Am. J. Health. Syst. Pharm. (2016)73(5):S35-S41.
[18] Chowdhry U, Jacques A, Karovitch A, Giguère P, Nguyen ML. Appropriateness of dabigatran and rivaroxaban prescribing for hospital inpatients. Can. J. Hosp. Pharm. (2016)69(3):194.
[19] Ashrafi F, Rezaie N, Mousavi S. New indications for dabigatran: A suggestion from a drug use evaluation study. J. Res. Pharm. Pract. (2017)6(4):211.